Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Projects
      • KL1333
      • NV354
      • Early programs
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2022
      • World Mitochondrial Disease Week 2021
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Press releases

  • All
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
17 April, 2014
Regulatory

NeuroVive presents medical breakthrough in cellular energy regulation

NeuroVive, a leading mitochondrial medicine company, is presenting a breakthrough in the company's work on energy regulation at the cellular level. Based on the UK company Selcia Ltd's medical chemist ...
Continue reading
17 April, 2014
Regulatory

NeuroVive Pharmaceutical’s 2013 Annual Report now available

Today, NeuroVive Pharmaceutical AB (publ) announced that the Annual Report for 2013 is available as PDF at www.neurovive.com, and can be read via the link below. The available report is in Swedish. An ...
Continue reading
10 April, 2014
Regulatory

NeuroVive Stock Now Trading in the USA on the OTC Market

NeuroVive Pharmaceutical AB stock shares were registered with the OTC Reporting Facility for Foreign shares in New York City with the ticker symbol NEVPF:US on March 20, 2014. NeuroVive trades on the ...
Continue reading
9 April, 2014
Regulatory

Invitation to the AGM of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting (AGM) of shareholders at 3 p.m. on Friday, 9 May 2014 a ...
Continue reading
31 March, 2014
Regulatory

Increased individual ownership through share exchange from Maas Biolab, LLC

One of NeuroVive's largest shareholders, Maas Biolab, LLC is reducing its ownership by 359,304 shares through a share exchange with its Swedish and US shareholders. This share exchange involves Maas B ...
Continue reading
31 March, 2014
Regulatory

NeuroVive Pharmaceutical AB—amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issues conducted by NeuroVive Pharmaceutical AB (p ...
Continue reading
28 March, 2014
Regulatory

NeuroVive presents significant hepatitis B data for its drug candidate NVP018

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to c ...
Continue reading
25 March, 2014
Regulatory

NeuroVive Pharmaceutical and A1M Pharma initiate research collaboration

NeuroVive Pharmaceutical AB (publ) and A1M Pharma AB (publ) have announced that the two companies are initiating a research collaboration in mitochondrial medicine. The partnership is governed by a co ...
Continue reading
13 March, 2014
Regulatory

NeuroVive Pharmaceutical AB—amendment number of shares and votes

As a result of new share issues conducted by NeuroVive Pharmaceutical AB (publ) ("NeuroVive"), as resolved by an Extraordinary General Meeting (EGM) on 13 December 2013, and decided by the Board of Di ...
Continue reading
10 March, 2014
Regulatory

NeuroVive starts collaboration to evaluate IPO of subsidiary in Taiwan

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is reporting that the company's subsidiary NeuroVive Pharmaceutical Asia Ltd., whose registered office is in Hong Kong, ha ...
Continue reading
19 February, 2014
Regulatory

NeuroVive: Year-End Report 1 Jan. 2013 till 31 Dec. 2013

NeuroVive consolidates positioning as leading mitochondrial medicine company
Continue reading
17 February, 2014
Regulatory

NeuroVive treats final patient in European phase III trial on CicloMulsion®

NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, has reported that the last of a total of 972 patients have now been enrolled and treated in its ongoing European phase III ...
Continue reading

Posts navigation

Older posts
Newer posts

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all